Prof. Pierre Fenaux, Head of the Department of  Hematology and Immunology at Assistance Publique-Hôpitaux de Paris Nord (Hôpitaux Saint-Louis, R Debré, Avicenne) is a leading expert in haematology with extensive experience in the treatment and management of myelodysplastic syndromes (MDS). In this interview, he discusses key considerations for first-line therapies in lower-risk MDS, the latest advances in treatment and the role of organizations like the European School of Hematology (ESH) in supporting haematologists.

In this interview, Prof. Robin Foà, a distinguished haematologist and now Emeritus Professor of Haematology at the Sapienza University of Rome, Italy, shares the inspirations and career-defining moments that led him to focus on haematology and leukaemia research. Initially trained ...

Watch this touchCONGRESS activity exploring advances in treatments for patients with CML, based on data from 2024 congresses, including EHA and ESH-iCMLf.

Isatuximab is a CD38-receptor targeted monoclonal antibody approved as a combination therapy for the treatment of RRMM in patients who have received 1 to 3 lines of prior therapy.

In our latest episode, we delve into the world of space medicine to explore how drug crystallization in microgravity could revolutionize biologic drug administration. Joining us is Dr Katie King, CEO of BioOrbit, to discuss the science, challenges, and technological advancements that could make space-based drug production a reality.

A new study published in Blood explores the potential for successful pregnancy after allogeneic stem cell transplantation (allo-SCT), providing new hope for women who have undergone this intense treatment.

Few alliances have impacted patient care as significantly as the Myeloproliferative Neoplasms Research Consortium (MPN-RC). Established in 2006, the MPN-RC is an international group dedicated to advancing research and developing innovative treatment strategies for myeloproliferative neoplasms (MPNs). In this episode, we speak with John Mascarenhas, MD, about the coalition's founding, operational mechanics and how their efforts have led to paradigm-shifting therapies in the field.

A recent review by Prof. Florence Pasquier and colleagues highlights the potential of olutasidenib, a selective, oral, small-molecule inhibitor of the mutant IDH1 enzyme, recently approved  by the FDA as treatment option for patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with isocitrate dehydrogenase 1 (IDH1) mutations.

The International Society on Thrombosis and Haemostasis (ISTH) has issued an evidence-based clinical practice guideline aimed at revolutionizing the treatment landscape for congenital haemophilia A and B. Hemophilia, a rare bleeding disorder caused by deficiencies in blood coagulation factors, affects individuals worldwide and demands intricate management strategies.